Tecentriq-Abraxane Combo Prolonging Survival in TNBC Patients, Phase 3 Trial Data Show

Tecentriq-Abraxane Combo Prolonging Survival in TNBC Patients, Phase 3 Trial Data Show
Tecentriq in combination with Abraxane, a chemotherapy, continues to prolong overall survival in adults with triple-negative breast cancer (TNBC) who test positive for the PD-L1 factor, a new interim analysis from a Phase 3 trial shows. These findings were detailed in an oral session, "IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC)," presented at the recent 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Tecentriq (atezolizumab) is an immune checkpoint inhibitor, (developed by Genentech, a Roche subsidiary), approved to treat certain types of cancer, including bladder and non-small cell lung cancer. An antibody, it is designed to bind to PD-L1, or programmed death-ligand 1, a substance produced by cancer cells. This effectively prevents PD-L1 from binding to its receptor, the PD-1 receptor, which can be found on the surface of immune cells. By doing so, Tecentriq blocks the signaling cascade that allows cancer cell
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.